ELVN
Income statement / Annual
Last year (2023), Enliven Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Enliven Therapeutics, Inc.'s net income was -$71.58 M.
See Enliven Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$297,000.00 |
$622,000.00 |
$99,000.00 |
$97,000.00 |
$33,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$297,000.00 |
-$622,000.00 |
-$99,000.00 |
-$97,000.00 |
-$33,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$64.57 M
|
$31.02 M
|
$20.47 M
|
$8.24 M
|
$19.01 M
|
$8.24 M
|
$7.92 M
|
| General & Administrative
Expenses |
$18.96 M
|
$7.77 M
|
$4.29 M
|
$1.08 M
|
$5.11 M
|
$2.44 M
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$33,000.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.96 M
|
$7.77 M
|
$4.29 M
|
$1.08 M
|
$5.07 M
|
$2.44 M
|
$987,000.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$9.68 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$83.53 M |
$38.79 M |
$24.76 M |
$9.32 M |
$24.08 M |
$10.68 M |
$8.91 M |
| Cost And Expenses |
$83.53 M |
$38.79 M |
$24.76 M |
$9.32 M |
$24.12 M |
$10.68 M |
$8.91 M |
| Interest Income |
$11.97 M |
$1.13 M |
$22,000.00 |
$31,000.00 |
$578,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$297,000.00
|
$215,000.00
|
$115,000.00
|
$97,000.00
|
$33,000.00
|
-$660,000.00
|
$0.00
|
| EBITDA |
-$81.93 M
|
-$38.58 M
|
-$24.65 M
|
-$9.27 M
|
-$23.43 M
|
-$11.34 M
|
$221,000.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$11.95 M
|
$1.13 M
|
$22,000.00
|
-$9.65 M
|
$653,000.00
|
-$660,000.00
|
$9.13 M
|
| Income Before Tax |
-$71.58 M |
-$37.66 M |
-$24.74 M |
-$18.97 M |
-$23.46 M |
-$11.34 M |
$221,000.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$88,000.00 |
-$22,000.00 |
-$31,000.00 |
$653,000.00 |
-$821,141.00 |
$221,000.00 |
| Net Income |
-$71.58 M |
-$37.75 M |
-$24.72 M |
-$18.94 M |
-$23.46 M |
-$11.34 M |
$0.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.01 |
-6.0273 |
-3.17 |
-14.1383 |
-5.4311 |
-2.6242 |
0 |
| EPS Diluted |
-2.01 |
-6.0273 |
-3.17 |
-14.1383 |
-5.4311 |
-2.6242 |
0 |
| Weighted Average Shares
Out |
$35.55 M
|
$6.25 M
|
$7.81 M
|
$3.48 M
|
$4.32 M
|
$4.32 M
|
$4.32 M
|
| Weighted Average Shares
Out Diluted |
$35.55 M
|
$6.25 M
|
$7.81 M
|
$3.48 M
|
$4.32 M
|
$4.32 M
|
$4.32 M
|
| Link |
|
|
|
|
|
|
|
